Press Release


WuXi AppTec Launches DNA Encoded Library (DEL) Service Package “DELight” to Expedite Early Drug Discovery

SHANGHAI, BOSTON, Sep. 3, 2019 - WuXi AppTec today announced its launch of DELight, a novel DNA Encoded Library (DEL) service package, providing cost-effective and efficient hit finding services to expedite early drug discovery and bring new medicines to patients faster.


WuXi AppTec Reports First Half 2019 Interim Results

SHANGHAI, August 19, 2019— WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a platform that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its financial results for the six months ended June 30, 2019 (“Reporting Period”).


WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections

SHANGHAI, 23 July, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit (ASU) in Shanghai and active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou, have successfully passed two inspections from the U.S. Food and Drug Administration (FDA) within the same week, with no Form 483s issued. This not only marks a milestone for WuXi STA on running a continual state of regulatory readiness, with real time GMP monitoring and an ingrained internal quality culture, but also shows its commitment on providing integrated R&D and manufacturing services with the highest quality standard for customers.

Media Center

Provide WuXi at a glance, media package and company photos for media to download

Upcoming Events

Discover Wuxi AppTec Conference and Event Information